Skip to main content

Table 6 Comparison of characteristics between RA patients who never achieved remission and those who achieved and maintained remission (case–control study, nested within the cohort)

From: Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity

Characteristic RA patients who achieved and maintained remission RA patients who never achieved sustained remission P value
( n= 46) ( n= 14)
Socio-demographic    
Female gender 40 (87%) 14 (100) 0.32
Age (years) 38.2 ± 10.5 38.7 ± 12.5 0.88
Years of formal education 10.5 ± 8.8 10 ± 7.7 0.43
Current smokers 5 (10.9) 0 (0) 0.33
Females with menopause (142 female) 2 (5) 1 (7) 1
Baseline BMI (kg/m2) 25.1 (22 to 27.5) 27.8 (23.1 to 30.4) 0.05
Disease characteristics    
Disease duration (months) 5.8 (4.1 to 7.7) 3.3 (1.6 to 6) 0.03
Patients with ACCP 38 (82.6) 13 (92.9) 0.67
Baseline DAS28 6 (4.6 to 6.8) 7.3 (6.5 to 7.8) 0.002
Baseline ESR (mm/hour) 24.5 (14.3 to 37) 43 (28.3 to 59.5) 0.012
Baseline CRP (mg/dl) 1 (0.3 to 3.4) 2.4 (1.4 to 6.1) 0.05
Baseline HAQ 1.4 (0.6 to 2) 2.3 (1.6 to 3) 0.008
Patients with erosions at baseline 5 (11) 0 (0) 0.33
Follow-up (months) 88 (58.5 to 108) 87 (57 to 108) 0.96
Incidental MetS 19 (41.3) 11 (78.6) 0.03
Comorbid conditions    
Patients with diabetes 1 (2.2) 0 (0) 1
Patients with hypertension 1 (2.2) 0 (0) 1
Patients with BMI ≥30 kg/m2 4 (8.7) 6 (42.9) 0.007
Treatment up to sustained remission a    
Number of DMARDs/patient 2 (2 to 2.5) 2.5 (2 to 2.75) 0.08
Patients with corticosteroids 30 (65.2) 9 (64.3) 1
  1. Data presented as n (%), mean ± standard deviation or median (range). ACCP, antibodies to cyclic citrullinated peptides; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; RA, rheumatoid arthritis. aIn those who never achieved remission, complete follow-up was considered.